Earning Analysis
Welcome to our in-depth analysis of Cue Biopharma Inc(CUE) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Cue Biopharma Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
CUE Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Cue Biopharma Inc reported performance for FY2024Q3, announced on 2024-11-14. The company achieved an EPS of -0.17, compared to analyst estimates of -0.20 by 15.00% . Revenue for the quarter reached 3.34M compared to expectations of 1.52M by 119.55% .
The stock price reacted with a 0.00% one-day change and a -27.33% five-day change following the earnings release. These movements reflect market reaction in Cue Biopharma Inc growth trajectory and strategic initiatives.
CUE Earnings Forecast
Looking ahead, Cue Biopharma Inc(CUE) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q4 project quarter revenue of 1.75M and an EPS of -0.10.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been No Change by 0%, while EPS estimates have been No Change by 0%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Upward by 75% . These revisions correlate with a -29.10% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Cue Biopharma Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between CUE's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
No Change

0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change

0.00%
In Past 3 Month
Revenue Estimates for Q4 2025
Revise Upward

+75%
In Past 3 Month
Stock Price
Go Down

-29.10%
In Past 3 Month
Currency: USD
--
Revenue Estimate-Annual FY 2025:7.38M
--
EPS Estimate-Annual FY 2025:-0.41
CUE Revenue and EPS Performance: A Historical Perspective
Cue Biopharma Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2024Q3 (2024-11-14,):
EPS: -0.17 (Actual) vs.-0.20 (Estimate) (15.00%)
Revenue: 3.34M (Actual) vs. 1.52M (Estimate) (119.55%)
Price Reaction: 0.00%(1-Day), -27.33%(5-Day)
FY2024Q1 (2024-05-09,):
EPS: -0.25 (Actual) vs.-0.30 (Estimate) (16.67%)
Revenue: 1.72M (Actual) vs. 1.21M (Estimate) (41.55%)
Price Reaction: 0.26%(1-Day), -14.14%(5-Day)
(2024-04-08,):
EPS: -0.28 (Actual) vs. (Estimate) (%)
Revenue: 0.00 (Actual) vs. 0.00 (Estimate) (%)
Price Reaction: 10.27%(1-Day), -5.41%(5-Day)
Earnings Reaction
The chart below shows how CUE performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CUE sees a -10.14% change in stock price 10 days leading up to the earnings, and a -6.42% change 10 days following the report. On the earnings day itself, the stock moves by +2.02%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2024, the stock changed -17.00% on the day following the earnings release and then changed by -18.67% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Cue Biopharma, Inc. (CUE) Q2 2024 Earnings Call Summary
The earnings call summary presents a mixed outlook. Financial management shows improvement with reduced cash burn and extended runway, but challenges remain. The company's clinical data is promising, with significant improvements in treatment efficacy and survival outcomes, which is positive. However, there are concerns about regulatory risks, competitive pressures, and dependency on partnerships. The Q&A section highlights strategic interest and potential partnerships, but also reveals management's vague responses, particularly regarding milestone negotiations. Without a share repurchase program or clear guidance, the overall sentiment remains neutral.
FAQ

What were the key highlights of CUE’s latest earnings report for FY2024Q3?
CUE reported its FY2024Q3 earnings on 2024-11-14, showcasing a revenue of 3.34M against an estimate of 1.52M, resulting in a 119.55% surprise. The EPS was -0.17, surpassing the expected -0.2 by 15% . The stock experienced a 0% price change on the earnings day and a -27.33% change over the next five days, reflecting market reactions to the results.

How did CUE’s stock price react after the FY2024Q3 earnings release?
Following CUE’s FY2024Q3 earnings announcement on 2024-11-14, the stock price moved by 0.00% on the day of the release. Over the subsequent five days, it saw a -27.33% change. Historically, CUE’s stock price tends to shift by an average of -10.14% in the 10 days leading up to earnings and -6.42% in the 10 days following, providing insight into potential market.

What are the revenue and EPS estimates for CUE for 2025/Q4?
For 2025/Q4, analysts estimate CUE’s annual revenue to reach 1.75M, while the EPS is projected at -0.10. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates Revise Upward by 75% over the past three months, indicating analyst expectation in the company’s performance.

How does CUE’s stock price correlate with earnings forecast revisions?
The correlation between CUE’s stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved Revise Upward by 75% . This trend suggests that price dips could present buying opportunities for investors.

What should investors expect from CUE’s next earnings report?
Based on historical trends, CUE’s stock price typically moves by -10.14% in the 10 days before its earnings and -6.42% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.10 and revenue of 1.75M.

What is the sentiment in Cue Biopharma, Inc. (CUE) Q2 2024 Earnings Call Summary?
The earnings call summary presents a mixed outlook. Financial management shows improvement with reduced cash burn and extended runway, but challenges remain. The company's clinical data is promising, with significant improvements in treatment efficacy and survival outcomes, which is positive. However, there are concerns about regulatory risks, competitive pressures, and dependency on partnerships. The Q&A section highlights strategic interest and potential partnerships, but also reveals management's vague responses, particularly regarding milestone negotiations. Without a share repurchase program or clear guidance, the overall sentiment remains neutral.